Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy.
Stefania FarcomeniSonia MorettiCaterina FimianiLucia Fontanelli SulekovaFenicia VescioLeonardo SernicolaMaria T MaggiorellaAnna Lisa RemoliOrietta PicconiLuciana MoscaRozenn EsvanElisa BiliottiMassimo CiccozziMarco SgarbantiGloria TalianiAlessandra BorsettiPublished in: Pathogens (Basel, Switzerland) (2021)
Our study suggests that, although patients achieved HCV eradication, the immune activation state in both HCV mono-infected and HCV/HIV co-infected patients remains elevated for a long time after the end of DAA therapy, despite an improvement of liver-specific outcomes, meanwhile highlighting the distinct immunophenotypic and inflammatory biomarker profile between the groups of patients.
Keyphrases
- hepatitis c virus
- human immunodeficiency virus
- end stage renal disease
- ejection fraction
- antiretroviral therapy
- newly diagnosed
- chronic kidney disease
- hiv infected
- peritoneal dialysis
- hiv positive
- prognostic factors
- hiv aids
- oxidative stress
- metabolic syndrome
- stem cells
- skeletal muscle
- helicobacter pylori infection
- insulin resistance
- cell therapy
- smoking cessation
- glycemic control